Efficacy and safety of neoadjuvant chemotherapy with oxaliplatin, 5-fluorouracil, and levofolinate for T3 or T4 stage II/III rectal cancer: the FACT trial

被引：0

作者：

Junichi Koike

Kimihiko Funahashi

Kazuhiko Yoshimatsu

Hajime Yokomizo

Hayato Kan

Takeshi Yamada

Hideyuki Ishida

Keiichiro Ishibashi

Yoshihisa Saida

Toshiyuki Enomoto

Kenji Katsumata

Masayuki Hisada

Hirotoshi Hasegawa

Keiji Koda

Takumi Ochiai

Kazuhiro Sakamoto

Hiroyuki Shiokawa

Shimpei Ogawa

Michio Itabashi

Shingo Kameoka

机构：

[1] Toho University School of Medicine,Department of Gastroenterological Surgery, Omori Medical Center

[2] Tokyo Women’s Medical University Medical Center East,Department of Surgery

[3] Nippon Medical School,Department of Gastrointestinal and Hepato

[4] Saitama Medical University,Biliary

[5] Toho University Ohashi Medical Center,Pancreatic Surgery

[6] Tokyo Medical University,Department of Digestive Tract and General Surgery, Saitama Medical Center

[7] Keio University School of Medicine,Department of Surgery

[8] Teikyo University Chiba Medical Center,Department of Digestive Surgery and Pediatric Surgery

[9] Tokyo Metropolitan Health and Medical Treatment Corporation,Department of Surgery

[10] Juntendo University,Department of Surgery

[11] Tokyo Women’s Medical University,Department of Surgery, Tobu Chiiki Hospital

[12] FACT Trial Group,Department of Coloproctological Surgery, Faculty of Medicine

来源：

Cancer Chemotherapy and Pharmacology | 2017年 / 79卷

关键词：

mFOLFOX6; Rectal cancer; Resectable; Neoadjuvant chemotherapy; Preoperative chemotherapy;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：519 / 525

页数：6

共 87 条

[1]

Folprecht G(2010)Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial Lancet Oncol 11 38-47

[2]

Gruenberger T(2013)Multicenter phase II study of modified FOLFOX6 as neoadjuvant chemotherapy for patients with unresectable liver-only metastases from colorectal cancer in Japan: ROOF study Int J Clin Oncol 18 335-342

[3]

Bechstein WO(2014)Neoadjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer Cancer Chemother Pharmacol 73 1079-1087

[4]

Takahashi T(2013)Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II trial Jpn J Clin Oncol 43 964-971

[5]

Shibata Y(2006)Key issues in reporting common cancer specimens: problems in pathologic staging of colon cancer Arch Pathol Lab Med 130 318-324

[6]

Tojima Y(2004)Preoperative versus postoperative chemoradiotherapy for rectal cancer N Eng J Med 351 1731-1740

[7]

Hasegawa J(2012)Preoperative versus postoperative chemoradiotherapy for rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years J Clin Oncol 30 1926-1933

[8]

Nishimura J(2006)Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer Br J Surg 93 1215-1223

[9]

Mizushima T(2012)Initial results of randomized controlled trial comparing clinical and pathological downstaging of rectal cancer after preoperative short-course radiotherapy or long-term chemoradiotherapy, both with delayed surgery Colorectal Dis 14 294-298

[10]

Uehara K(2006)Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203 J Clin Oncol 24 4620-4625

← 1 2 3 4 5 6 7 8 9 →